Results For "General"

843 News Found

Dr. Reddy's initiates process for emergency use authorization of Sputnik V

News | February 20, 2021

Dr. Reddy's initiates process for emergency use authorization of Sputnik V

Dr. Reddy's will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by 2pt February 2021.

Dr. Reddy’s gets approval for Sputnik V Phase 3 trial

News | January 16, 2021

Dr. Reddy’s gets approval for Sputnik V Phase 3 trial

The phase 3 clinical trial of Sputnik V will be conducted on 1,500 subjects as part of the randomized, double blind, parallel group placebo controlled study in India.

Dr. Reddy’s seeks approval to continue Phase 3 trial

News | January 13, 2021

Dr. Reddy’s seeks approval to continue Phase 3 trial

The Phase 2 study of Sputnik V was conducted on 100 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India.

Latest Stories

Fermenta receives CEP by EDQM for Vitadee 100 SD

Zydus completes acquisition of 85.6% stake in Amplitude Surgical

Bliss GVS Pharma posts Q1 FY26 PAT higher at Rs. 43.03 Cr

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews

India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant

India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant

Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India

Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India

Dr. R. Ananthanarayanan CEO, Sajjan India

Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries

Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries

Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging